Jingsong Wang – Chairman & CEO, Harbour BioMed, China

15.04.2020
PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since we last met them in January 2019, including their March USD 75 million Series B+ fundraising round and their preparations for several Phase II/III pivotal to come later this year.  
From the time of Harbour BioMed’s inception in 2016, we have always set out to be a patient-centric global biotech company with multiple forms of value generation for our shareholders
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
China, Harbour BioMed, Biotech, IPO, Strategy

Related Interviews

Dun Yang – President & CEO, Anticancer Bioscience

Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach…

Sizhen Wang – CEO & Co-Founder, Genetron Health

Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen…

Haijun Dong – CEO, BioDuro-Sundia

Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world,…

Related Articles

China / Emerging Pharmacovigilance Framework Ensuring Safe COVID-19 Vaccines

PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…

China / 61.7% Profit Hit Needed for NDRL Listing; Local mRNA Rush; BioNTech Continues Push for Vaccine Approval

Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…

Global / PharmaBoardroom’s Top Five Op-Eds of 2021

PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca…

Latest Report

Singapore Pharma Report 2021

Related Content

China
Harbour BioMed
Biotech
IPO
Strategy